Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma

David Price, Linda Kemp, Erika Sims, Julie von Ziegenweidt, Prakash Navaratnam, Amanda J Lee, Alison Chisholm, Elizabeth V. Hillyer, Gokul Gopalan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

AIMS: Retrospective database study comparing upper and lower airway-related outcomes for patients with rhinitis and co-morbid asthma receiving mometasone furoate--an intranasal corticosteroid with low systemic bioavailability--or an oral antihistamine. METHODS: 395 patients prescribed intranasal mometasone were matched on 10 demographic and respiratory-related criteria in a 1:2 ratio to 790 patients prescribed oral antihistamine. Asthma and rhinitis control were assessed over one year using predefined composite proxy measures. RESULTS: Asthma control was achieved by 309/395 (78.2%) versus 580/790 (73.4%; p=0.071) patients in the mometasone and antihistamine cohorts, respectively. Rhinitis control was achieved by 293 (74.2%) versus 539 (68.2%; p=0.035), respectively. The adjusted odds ratios for antihistamines, relative to mometasone, were 0.71 (95% CI, 0.52-0.98) for achieving asthma control and 0.74 (95% CI, 0.56-0.97) for achieving rhinitis control. CONCLUSIONS: Patients with rhinitis and co-morbid asthma initiating rhinitis therapy achieved significantly better upper as well as lower airway outcomes with intranasal mometasone than with oral antihistamine.
Original languageEnglish
Pages (from-to)266-273
Number of pages8
JournalPrimary Care Respiratory Journal
Volume19
Issue number3
Early online date22 Jun 2010
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Mometasone Furoate
Histamine Antagonists
Rhinitis
Observational Studies
Asthma
Proxy
Biological Availability
Adrenal Cortex Hormones
Retrospective Studies
Odds Ratio
Demography
Databases

Keywords

  • antihistamine
  • asthma
  • control
  • mometasone furoate
  • one airway
  • rhinitis

Cite this

Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. / Price, David; Kemp, Linda; Sims, Erika; von Ziegenweidt, Julie; Navaratnam, Prakash; Lee, Amanda J; Chisholm, Alison; Hillyer, Elizabeth V.; Gopalan, Gokul.

In: Primary Care Respiratory Journal, Vol. 19, No. 3, 09.2010, p. 266-273.

Research output: Contribution to journalArticle

Price, D, Kemp, L, Sims, E, von Ziegenweidt, J, Navaratnam, P, Lee, AJ, Chisholm, A, Hillyer, EV & Gopalan, G 2010, 'Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma' Primary Care Respiratory Journal, vol. 19, no. 3, pp. 266-273. https://doi.org/10.4104/pcrj.2010.00040
Price, David ; Kemp, Linda ; Sims, Erika ; von Ziegenweidt, Julie ; Navaratnam, Prakash ; Lee, Amanda J ; Chisholm, Alison ; Hillyer, Elizabeth V. ; Gopalan, Gokul. / Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. In: Primary Care Respiratory Journal. 2010 ; Vol. 19, No. 3. pp. 266-273.
@article{30ad47c185de4592bc2abc3dd1c2714e,
title = "Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma",
abstract = "AIMS: Retrospective database study comparing upper and lower airway-related outcomes for patients with rhinitis and co-morbid asthma receiving mometasone furoate--an intranasal corticosteroid with low systemic bioavailability--or an oral antihistamine. METHODS: 395 patients prescribed intranasal mometasone were matched on 10 demographic and respiratory-related criteria in a 1:2 ratio to 790 patients prescribed oral antihistamine. Asthma and rhinitis control were assessed over one year using predefined composite proxy measures. RESULTS: Asthma control was achieved by 309/395 (78.2{\%}) versus 580/790 (73.4{\%}; p=0.071) patients in the mometasone and antihistamine cohorts, respectively. Rhinitis control was achieved by 293 (74.2{\%}) versus 539 (68.2{\%}; p=0.035), respectively. The adjusted odds ratios for antihistamines, relative to mometasone, were 0.71 (95{\%} CI, 0.52-0.98) for achieving asthma control and 0.74 (95{\%} CI, 0.56-0.97) for achieving rhinitis control. CONCLUSIONS: Patients with rhinitis and co-morbid asthma initiating rhinitis therapy achieved significantly better upper as well as lower airway outcomes with intranasal mometasone than with oral antihistamine.",
keywords = "antihistamine, asthma, control, mometasone furoate, one airway, rhinitis",
author = "David Price and Linda Kemp and Erika Sims and {von Ziegenweidt}, Julie and Prakash Navaratnam and Lee, {Amanda J} and Alison Chisholm and Hillyer, {Elizabeth V.} and Gokul Gopalan",
year = "2010",
month = "9",
doi = "10.4104/pcrj.2010.00040",
language = "English",
volume = "19",
pages = "266--273",
journal = "Primary Care Respiratory Journal",
issn = "1471-4418",
publisher = "Primary Care Respiratory Society UK",
number = "3",

}

TY - JOUR

T1 - Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma

AU - Price, David

AU - Kemp, Linda

AU - Sims, Erika

AU - von Ziegenweidt, Julie

AU - Navaratnam, Prakash

AU - Lee, Amanda J

AU - Chisholm, Alison

AU - Hillyer, Elizabeth V.

AU - Gopalan, Gokul

PY - 2010/9

Y1 - 2010/9

N2 - AIMS: Retrospective database study comparing upper and lower airway-related outcomes for patients with rhinitis and co-morbid asthma receiving mometasone furoate--an intranasal corticosteroid with low systemic bioavailability--or an oral antihistamine. METHODS: 395 patients prescribed intranasal mometasone were matched on 10 demographic and respiratory-related criteria in a 1:2 ratio to 790 patients prescribed oral antihistamine. Asthma and rhinitis control were assessed over one year using predefined composite proxy measures. RESULTS: Asthma control was achieved by 309/395 (78.2%) versus 580/790 (73.4%; p=0.071) patients in the mometasone and antihistamine cohorts, respectively. Rhinitis control was achieved by 293 (74.2%) versus 539 (68.2%; p=0.035), respectively. The adjusted odds ratios for antihistamines, relative to mometasone, were 0.71 (95% CI, 0.52-0.98) for achieving asthma control and 0.74 (95% CI, 0.56-0.97) for achieving rhinitis control. CONCLUSIONS: Patients with rhinitis and co-morbid asthma initiating rhinitis therapy achieved significantly better upper as well as lower airway outcomes with intranasal mometasone than with oral antihistamine.

AB - AIMS: Retrospective database study comparing upper and lower airway-related outcomes for patients with rhinitis and co-morbid asthma receiving mometasone furoate--an intranasal corticosteroid with low systemic bioavailability--or an oral antihistamine. METHODS: 395 patients prescribed intranasal mometasone were matched on 10 demographic and respiratory-related criteria in a 1:2 ratio to 790 patients prescribed oral antihistamine. Asthma and rhinitis control were assessed over one year using predefined composite proxy measures. RESULTS: Asthma control was achieved by 309/395 (78.2%) versus 580/790 (73.4%; p=0.071) patients in the mometasone and antihistamine cohorts, respectively. Rhinitis control was achieved by 293 (74.2%) versus 539 (68.2%; p=0.035), respectively. The adjusted odds ratios for antihistamines, relative to mometasone, were 0.71 (95% CI, 0.52-0.98) for achieving asthma control and 0.74 (95% CI, 0.56-0.97) for achieving rhinitis control. CONCLUSIONS: Patients with rhinitis and co-morbid asthma initiating rhinitis therapy achieved significantly better upper as well as lower airway outcomes with intranasal mometasone than with oral antihistamine.

KW - antihistamine

KW - asthma

KW - control

KW - mometasone furoate

KW - one airway

KW - rhinitis

U2 - 10.4104/pcrj.2010.00040

DO - 10.4104/pcrj.2010.00040

M3 - Article

VL - 19

SP - 266

EP - 273

JO - Primary Care Respiratory Journal

JF - Primary Care Respiratory Journal

SN - 1471-4418

IS - 3

ER -